Company profile: Complete Genomics
1.1 - Company Overview
Company description
- Provider of DNA sequencing platforms for human genome sequencing and analysis, supporting commercial-scale research into genetic mechanisms underlying drug responses and complex diseases. Offerings include DNBSEQ-T7 and DNBSEQ-T20x2 ultra-high throughput sequencers, DNBSEQ-G400 high throughput, DNBSEQ-G99 fast mid throughput, DNBSEQ-E25 portable, and CoolMPS for genomic analysis.
Products and services
- DNBSEQ-T7: Complete Genomics engineers the DNBSEQ-T7, a commercial-scale, ultra-high throughput DNA sequencing platform that executes human genome sequencing and analysis, accelerating research into drug responses and complex diseases
- DNBSEQ-T20x2: Complete Genomics architects the DNBSEQ-T20x2, a research-grade, ultra-high throughput sequencer for genomic research, enabling human genome sequencing and analysis and commercial-scale exploration of drug responses and complex disease genetics
- DNBSEQ-G400: Complete Genomics builds the DNBSEQ-G400, a lab-optimized, high throughput DNA sequencing platform executing human genome sequencing and analysis, enabling affordable, high-quality genomic research on drug responses and complex diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Complete Genomics
Arima Genomics
HQ: United States
Website
- Description: Provider of 3D genomics solutions including Arima-HiC to capture chromatin organization, Arima Capture-HiC for high-resolution targeted chromatin conformation, and Arima-HiChIP for protein-DNA interaction analysis; plus genome assembly of reference-quality, chromosome-spanning assemblies, and cancer genomics and human health offerings delivering insights into disease mechanisms, biomarkers, and therapeutic targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arima Genomics company profile →
B-MoGen
HQ: United States
Website
- Description: Provider of genome engineering solutions, including the TcBuster Transposon System, a non-viral genetic modification method for delivering therapeutic payloads to diverse cell types, enabling rapid transgenic mammalian cell generation, multigene transfer, and CRISPR-mediated knockouts; and ScaleReady, a partnership that reduces complexity and cost in immune cell therapy and supports scalable immune cell expansion with platform, process, and product continuity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full B-MoGen company profile →
Akoya Biosciences
HQ: United States
Website
- Description: Provider of end-to-end spatial biology solutions for high-parameter tissue analysis from biomarker discovery through clinical and translational research, enabling more precise therapies in immuno-oncology and drug development; offerings include PhenoCycler for spatial phenotyping at unprecedented speeds and PhenoImager for comprehensive tissue analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akoya Biosciences company profile →
Atomic Alchemy
HQ: United States
Website
- Description: Provider of radioisotopes for medical, research, exploration, and industrial use, aiming to establish a reliable domestic supply in the U.S. for medical radioisotopes such as molybdenum-99, in a market that currently lacks a dedicated domestic supplier and relies on university research reactors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atomic Alchemy company profile →
Immunologix
HQ: United States
Website
- Description: Provider of antibody-based therapeutics, producing human monoclonal antibodies targeting viral, bacterial, and tumor antigens, as well as human auto antigens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunologix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Complete Genomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Complete Genomics
2.2 - Growth funds investing in similar companies to Complete Genomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Complete Genomics
4.2 - Public trading comparable groups for Complete Genomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →